相关实验视频

Updated: Jul 7, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

贝利穆马布的类固醇节约作用:对现实世界的数据进行了回顾性观察研究的结果

Karen Worley¹, Scott Milligan², Bernard Rubin³

¹GSK, Value, Evidence & Outcomes, Cincinnati, Ohio, USA karen.x.worley@gsk.com.

Lupus science & medicine

|December 22, 2023

概括

在全身性红斑狼 (SLE) 患者中使用贝利穆马布显著降低了口服皮质类固醇 (OCS) 的剂量和整体使用. 这种现实世界的证据支持belimumab.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

系统性红斑狼 (SLE) 管理通常涉及口服皮质类固醇 (OCS),与显著的毒性相关.
贝利穆马布是一种已批准用于SLE治疗的生物药物.
在现实临床实践中评估贝利穆马布的类固醇节约潜力至关重要.

研究的目的:

为了比较口服皮质类固醇 (OCS) 在SLE患者在开始贝利马布治疗之前和之后的使用情况.
评估贝利穆马布对OCS剂量和持续时间的影响在美国风湿病学网络中.

主要方法:

使用PIONEER-Rheumatology数据库进行回顾性队列研究.
包括2012年至2021年间开始使用贝利姆巴的成年SLE患者,其启动前数据>180天,启动后数据>360天.
评估OCS使用的变化,包括患者的比例,平均剂量和每日剂量,在贝利马布前后期间.

主要成果:

在接受贝利马布的608名患者中,56.3%在基线使用了OCS.
在OCS使用者中,贝利马布的开始导致OCS使用在首次 (78.4%) 和第二次 (64.9%) 开始后的6个月期间显著减少.
观察到平均总OCS剂量,平均每日OCS剂量和低剂量OCS (≤5mg/天和≤7.5mg/天) 的患者比例的显著下降.

结论:

在患有SLE的患者中,贝利马布治疗与口服皮质类固醇 (OCS) 的使用和剂量显著减少有关.
这些发现提供了现实世界的证据,支持belimumab的类固醇节约作用.
在SLE管理中,贝利马布可能有助于减轻与OCS相关的毒性.

关键词:

自身免疫性疾病自身免疫性疾病葡萄糖皮质类药物是什么红斑狼,全身性红斑狼

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...